Replies to post #483818 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

Christopher U. Missling, PhD, MS, MBA, is the President and CEO of Anavex

https://www.anavex.com/about-us

GOD bless,

[kund]

The biggest issue I have with AVXL is that it has never received the respect it deserves

Respect has to be earned, and this company hasn't earned it due to its poor execution. The CEO has lied repeatedly, hidden data, and delayed releases to suit his narrative. He lost whatever respect he had after the Rett Avatar AUC and the AD odds ratio. Additionally, he has surrounded himself with questionable employees who contribute nothing but are still paid very well.

[BIOChecker4]

“The biggest issue I have with AVXL is that it has never received the respect it deserves.”

Wrong. Respect must be earned. Anavex has not earned respect.

[Hoskuld]

BAR123, a couple of these execs, Missling included, get all their compensation and have nearly all their wealth from and in Anavex. No one expects someone with 95% of their wealth in Anavex to buy...more Anavex shares.

You want yet another executive that will report to CM? No thanks.

Shares go up and shares go down. We are actually lucky that Anavex shares do BOTH. Some pre-revenue biotech companies only see their shares go one way. Is $8 crazy? Nope. It will be crazy if 3-71 P2 readout is awesome. And it would be insane if MAA is approved. But, right now? Anything between $6-$26 is possible right now because there is no definitive revenue foundation in place yet.

If you are sincere and frustrated then you are not alone. I have a couple of real complaints too, most revolving around trial design and bulls**t schedule guidance (e.g., Rett trial restart, PD trial update by end of January, etc.) You can bet your bottom dollar that 3-71 will not read out in H1 - that was more puffery. But, the MAA workflow marches on, trials will end, new trials will start. I think we both have to put our frustrations away for now and just patiently wait for the material events that are coming.